Reviewer’s report

**Title:** Boceprevir for Previously Untreated Patients with Chronic Hepatitis C Genotype 1 Infection: A US-Based Cost-Effectiveness Modeling Study

**Version:** 5 **Date:** 25 February 2013

**Reviewer:** Gaby Sroczynski

**Reviewer’s report:**

The author’s objective was to evaluate the clinical long-term effects and cost-effectiveness of antiviral treatment strategies with boceprevir compared to standard treatment in previously untreated patients with HCV-genotype 1 infection. The evaluation is performed using a decision-analytic model for the U.S. health care context from the payer’s perspective. The authors used a model divided by two phases, first the treatment phase and second the natural history of chronic hepatitis C progression to evaluate the research question. The research topic is important and the methods used are suitable.

The authors thoroughly revised their manuscript regarding the main points of my review. I highly recommend to publish this article.

**Level of interest:** An article of outstanding merit and interest in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests.